Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05946213 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableStart date: Nov 13, 2023 to Dec 14, 2023Study sites: 240 to 273 · Completion date: Mar 31, 2041 to Mar 31, 2036 · Interventions: External Beam Radiation Therapy (Radiation), Stereotactic Body Radiation Therapy (Radiation) to Computed Tomography (Procedure), External Beam Radiation Therapy (Radiation), Magnetic Resonance Imaging (Procedure), Quality-of-Life… · 5 morev8Show 8 more changesShow less
Study sites: 240 to 273
Completion date: Mar 31, 2041 to Mar 31, 2036
Interventions: External Beam Radiation Therapy (Radiation), Stereotactic Body Radiation Therapy (Radiation) to Computed Tomography (Procedure), External Beam Radiation Therapy (Radiation), Magnetic Resonance Imaging (Procedure), Quality-of-Life…
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.